# (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

> **NCT02039726** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 367 (actual)

## Conditions studied

- AML

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Salvage Chemotherapy

## Key facts

- **NCT ID:** NCT02039726
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2018-02-22
- **Final completion:** 2020-09-08
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039726, "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02039726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*